Tuesday June 27th 2017

12. Co-existence of primary progressive MS and CMT1A

A 48-year old man presented with a 20-year history of neurological symptoms. He reported slowly progressive changes in gait, mild right leg weakness and subtle short-term memory problems. There was no history of discrete relapses and no family history of neurological disease. The neurological examination revealed upper and lower limb weakness, marked lower limb spasticity, globally brisk reflexes and extensor plantar responses.MRI of the brain demonstrated white matter T2/FLAIR hyperintensities with extensive pericallosal involvement and MRI of the spinal cord revealed lesions in the thoracic cord suggestive of demyelination. Somatosensory and visual evoked potentials were markedly delayed and oligoclonal bands were detected in cerebrospinal fluid, consistent with multiple sclerosis. Nerve…

Link:

12. Co-existence of primary progressive MS and CMT1A

Leave a Comment

More from category

Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…
Are static and functional balance abilities related in individuals with Multiple Sclerosis? – Pau M, Porta M, Coghe G, Corona F, Pilloni G, Lorefice…

BACKGROUND: In people with Multiple Sclerosis (pwMS), balance assessment is essential in estimating the risk of falls, [Read More]

CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis
CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis CHMP Recommends Cladribine (Mavenclad) for Multiple Sclerosis

The European Medicines Agency ’ s Committee for Medicinal Products for Human Use recommends approval of cladribine to [Read More]

Germany’s Merck gets EU backing for oral MS drug
Germany’s Merck gets EU backing for oral MS drug

FRANKFURT (Reuters) - Germany's Merck KGaA has won a key recommendation to become a late entrant to the market for oral [Read More]

New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…
New data at EAN show Roche ’s OCREVUS (ocrelizumab) significantly reduced multiple measures of disease progression in relapsing and primary…

Roche announced today that new post-hoc analyses from the OCREVUS ™ (ocrelizumab) Phase III clinical trial programme [Read More]

MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation
MS Society Hosts Joint Congressional Briefing on the Value of Rehabilitation

/About-the-Society/News/Society-Hosts-Joint-Congressional-Briefing-on-the [Read More]